N18.31

Chronic kidney disease, stage 3a

## Overview of Chronic Kidney Disease Stage 3a\nChronic Kidney Disease (CKD) is a progressive loss of kidney function over time. Stage 3a CKD is defined by a glomerular filtration rate (GFR) persistently between 45 and 59 mL/min/1.73m² for at least three months, with or without markers of kidney damage (such as albuminuria, hematuria, or structural abnormalities). This stage represents a moderate decline in kidney function, where the kidneys are still functioning but are no longer able to filter waste and excess fluid from the blood as efficiently as healthy kidneys.\n\n### Pathophysiology\nThe kidneys contain millions of tiny filtering units called nephrons. In CKD, nephrons are progressively damaged and destroyed, leading to a reduction in the GFR. This damage can be initiated by various conditions, most commonly diabetes and hypertension, but also glomerulonephritis, polycystic kidney disease, and prolonged use of certain medications. As nephrons are lost, the remaining healthy nephrons undergo compensatory hypertrophy and hyperfiltration to maintain overall kidney function. However, this compensatory mechanism is ultimately detrimental, leading to further injury and scarring (glomerulosclerosis and tubulointerstitial fibrosis). The sustained reduction in GFR at stage 3a indicates a significant loss of functioning nephron mass, affecting the kidney's ability to regulate fluid and electrolyte balance, excrete waste products (urea, creatinine), produce hormones (erythropoietin, active vitamin D), and maintain acid-base balance. The progressive nature means that without intervention, kidney function can continue to decline, potentially advancing to later stages of CKD and eventually end-stage renal disease (ESRD).\n\n### Clinical Presentation\nCKD stage 3a is often subtle in its clinical presentation, with many individuals remaining asymptomatic. However, as kidney function begins to decline moderately, some patients may experience non-specific symptoms. These can include fatigue, weakness, reduced exercise tolerance due to anemia (early stages of which may begin here), and mild swelling in the ankles or feet (edema). Changes in urination, such as nocturia (frequent nighttime urination), may also occur. Blood pressure may become more difficult to control, and electrolyte imbalances, particularly mild hyperkalemia or hypocalcemia, may start to develop. Bone mineral disorders and metabolic acidosis, while more prominent in later stages, can begin to manifest subtly.\n\n### Diagnostic Criteria\nThe diagnosis of CKD stage 3a is primarily based on persistent laboratory findings. The key criteria include:\n* **Estimated Glomerular Filtration Rate (eGFR):** An eGFR between 45 and 59 mL/min/1.73m² maintained for at least three months. This is typically calculated using creatinine-based equations (e.g., CKD-EPI or MDRD).\n* **Evidence of Kidney Damage:** While not strictly required for staging based solely on GFR, evidence of kidney damage helps confirm the diagnosis of CKD. This includes:\n * **Albuminuria:** Presence of albumin in the urine, quantified by urine albumin-to-creatinine ratio (uACR). An uACR > 30 mg/g (or > 3 mg/mmol) indicates albuminuria.\n * **Hematuria:** Persistent presence of blood in the urine, not due to other causes.\n * **Structural abnormalities:** Detected by imaging (e.g., ultrasound, CT scan), such as polycystic kidneys, hydronephrosis, or small, scarred kidneys.\n * **Histological abnormalities:** Identified through kidney biopsy, if indicated.\n\n### Standard of Care\nManagement of CKD stage 3a focuses on slowing the progression of kidney disease, managing complications, and reducing cardiovascular risk. Key components include:\n* **Blood Pressure Control:** Aggressive management of hypertension, typically targeting a blood pressure of <130/80 mmHg, often utilizing ACE inhibitors or Angiotensin Receptor Blockers (ARBs), which have renoprotective effects.\n* **Glycemic Control:** Strict control of blood glucose in diabetic patients to prevent further kidney damage. SGLT2 inhibitors are increasingly recommended due to their proven renoprotective benefits.\n* **Lifestyle Modifications:** Dietary changes (reducing sodium intake, limiting protein, phosphorus, and potassium as needed), regular exercise, maintaining a healthy weight, and smoking cessation.\n* **Medication Management:** Avoiding nephrotoxic drugs (e.g., NSAIDs), careful use of diuretics for fluid overload. Consideration of SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (e.g., finerenone) where indicated to further reduce progression and cardiovascular events.\n* **Anemia Management:** Monitoring hemoglobin levels and addressing anemia with iron supplementation or erythropoiesis-stimulating agents (ESAs) if indicated.\n* **Bone and Mineral Disorder:** Monitoring calcium, phosphorus, PTH, and vitamin D levels, and managing abnormalities with phosphate binders, vitamin D analogs, or calcimimetics.\n* **Regular Monitoring:** Close follow-up with regular blood tests (eGFR, electrolytes, bone minerals) and urine tests (uACR) every 3-6 months. Referral to a nephrologist is often appropriate at this stage to optimize management and prepare for potential future progression.

Clinical Symptoms

  • Fatigue
  • Weakness
  • Reduced exercise tolerance
  • Mild swelling in ankles or feet (edema)
  • Nocturia (frequent nighttime urination)
  • Muscle cramps
  • Itching (pruritus)
  • Loss of appetite
  • Nausea
  • Difficulty concentrating
  • Shortness of breath (due to anemia or fluid overload)
  • Bone pain
  • Pale skin (due to anemia)

Common Causes

  • Diabetes mellitus (Type 1 and Type 2) - leading cause of CKD
  • Hypertension (high blood pressure) - second leading cause
  • Glomerulonephritis (inflammation of the kidney's filtering units)
  • Polycystic kidney disease (PKD) and other inherited kidney diseases
  • Obstructive nephropathy (e.g., kidney stones, enlarged prostate, tumors blocking urine flow)
  • Recurrent kidney infections (pyelonephritis)
  • Vasculitis (inflammation of blood vessels)
  • Systemic lupus erythematosus (SLE) and other autoimmune diseases
  • Prolonged use of certain medications (e.g., NSAIDs, some antibiotics, lithium)
  • Atherosclerosis of renal arteries (renal artery stenosis)
  • Reflux nephropathy (urine flows back into the kidneys)
  • Drug abuse (e.g., intravenous drug use leading to specific kidney diseases)
  • Heavy metal poisoning

Documentation & Coding Tips

Clearly document the estimated Glomerular Filtration Rate (eGFR) and the basis for chronic kidney disease (CKD) staging. State the stage explicitly.

Example: Pt is a 68 y/o female with known CKD. Recent labs show an eGFR of 52 mL/min/1.73m2 (MDRD formula, stable over 9 months), confirming Chronic Kidney Disease, Stage 3a (N18.31). Her urine albumin-creatinine ratio (UACR) is 45 mg/g, indicating persistent moderate albuminuria. Managed with ACE inhibitor for renoprotection.

Billing Focus: Documentation of the eGFR value and duration (e.g., 'stable over 9 months') validates chronicity and stage. Mentioning the formula used for eGFR calculation adds specificity. Persistent albuminuria adds to the clinical picture and supports the chronic nature.

Identify and document the underlying etiology of CKD whenever possible, as this impacts management and coding specificity.

Example: Type 2 Diabetes Mellitus with Diabetic Nephropathy (E11.22) is the primary etiology for this patient's Chronic Kidney Disease, Stage 3a (N18.31). Patient's A1c is 7.2%, indicating fair glycemic control, though microalbuminuria persists. BP controlled at 130/78 with Lisinopril.

Billing Focus: Linking the CKD directly to an etiology (e.g., 'Diabetic Nephropathy') provides crucial specificity for both the diabetes and CKD codes. This allows for combination coding and demonstrates medical necessity for related services.

Document all associated complications and comorbidities, ensuring they are linked to the CKD where clinically appropriate.

Example: Patient presents with fatigue and dyspnea on exertion. Labs reveal normocytic anemia (D63.1 - Anemia in chronic kidney disease, stage 3) with Hgb 10.5 g/dL, consistent with CKD-related anemia. Patient also has uncontrolled essential hypertension (I10) contributing to CKD progression and requires adjustment of antihypertensives.

Billing Focus: Explicitly linking 'anemia' to 'chronic kidney disease, stage 3' allows for the specific coding of D63.1. Documenting 'uncontrolled essential hypertension contributing to CKD progression' solidifies the relationship between these conditions.

Specify the patient's current management plan, including medication adjustments, dietary recommendations, and monitoring strategies.

Example: Plan: Continue ACE inhibitor (Lisinopril), encourage low-sodium and low-protein diet. Will monitor eGFR and UACR q3 months. Discussed avoiding NSAIDs and other nephrotoxic agents. Referral to Nephrology for further evaluation and management of CKD Stage 3a.

Billing Focus: Detailing the management plan (medication, diet, monitoring) supports the complexity of medical decision making (MDM) for Evaluation and Management (E/M) services, justifying higher E/M levels. Referral to a specialist (Nephrology) further indicates complex care.

Distinguish between acute kidney injury (AKI) superimposed on CKD and progression of CKD.

Example: Patient admitted with acute worsening of kidney function (eGFR 38 mL/min/1.73m2, baseline 52 mL/min/1.73m2) secondary to severe dehydration. This is an Acute Kidney Injury, Stage 1, superimposed on Chronic Kidney Disease, Stage 3a. Patient's CKD baseline (N18.31) remains, and acute injury (N17.9) is being treated. Upon rehydration, eGFR improved to 49 mL/min/1.73m2, still reflecting CKD 3a.

Billing Focus: Clearly documenting both N17.9 (Acute kidney failure, unspecified) and N18.31 is critical for accurate billing, as it signifies two distinct conditions. The narrative distinguishes transient AKI from the underlying chronic state.

Relevant CPT Codes

Related Diagnoses

Hierarchy